Published in J Gastrointest Oncol on December 01, 2013
KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients. World J Gastroenterol (2015) 0.81
Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. PLoS One (2015) 0.80
Comparison of gene expression of SOX2 and OCT4 in normal tissue, polyps, and colon adenocarcinoma using immunohistochemical staining. Adv Biomed Res (2015) 0.75
Lessons from hereditary colorectal cancer. Cell (1996) 25.73
Clues to the pathogenesis of familial colorectal cancer. Science (1993) 14.52
Microsatellite instability in cancer of the proximal colon. Science (1993) 14.51
Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature (1993) 12.74
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
Hereditary colorectal cancer. N Engl J Med (2003) 11.86
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med (2005) 9.39
Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res (1997) 8.88
Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med (1998) 8.47
Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology (2000) 8.41
Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol (2005) 8.15
Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol (2002) 5.91
Eukaryotic DNA mismatch repair. Curr Opin Genet Dev (1999) 5.34
Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med (2001) 5.22
Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med (2006) 4.95
Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med (1996) 4.87
Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res (1997) 4.61
Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells. Science (1995) 4.48
Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol (2000) 3.98
Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology (1997) 3.97
Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A (1998) 3.90
Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res (1998) 3.36
Conversion of diploidy to haploidy. Nature (2000) 3.28
Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res (1994) 3.25
Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol (2005) 3.19
MLH1, PMS1, and MSH2 interactions during the initiation of DNA mismatch repair in yeast. Science (1994) 3.19
Deficient DNA mismatch repair: a common etiologic factor for colon cancer. Hum Mol Genet (2001) 3.15
Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. J Natl Cancer Inst (2001) 3.02
Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA (2004) 2.99
Histopathological identification of colon cancer with microsatellite instability. Am J Pathol (2001) 2.90
AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology (2001) 2.63
Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst (1995) 2.62
The role of DNA mismatch repair in drug resistance. Clin Cancer Res (1998) 2.49
Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res (2002) 2.33
Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol (2001) 2.29
Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet (2000) 2.05
The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med (2003) 1.84
Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified. J Pathol (2005) 1.84
Efficient detection of hereditary nonpolyposis colorectal cancer gene carriers by screening for tumor microsatellite instability before germline genetic testing. Gastroenterology (2001) 1.78
P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res (2001) 1.74
DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet (2002) 1.68
Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res (1996) 1.63
Replication errors: cha(lle)nging the genome. EMBO J (1998) 1.62
p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology (2000) 1.52
Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med (2001) 1.50
Value of pedigree/clinical data, immunohistochemistry and microsatellite instability analyses in reducing the cost of determining hMLH1 and hMSH2 gene mutations in patients with colorectal cancer. Eur J Cancer (2000) 1.31
The clinical importance and prognostic implications of microsatellite instability in sporadic cancer. Eur J Surg Oncol (2003) 1.24
HMSH6 alterations in patients with microsatellite instability-low colorectal cancer. Cancer Res (2000) 1.20
Extensive molecular screening for hereditary non-polyposis colorectal cancer. Br J Cancer (2000) 1.15
Bethesda guidelines: relation to microsatellite instability and MLH1 promoter methylation in patients with colorectal cancer. Ann Intern Med (2001) 1.15
The reliability of immunohistochemistry as a prescreening method for the diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC)--results of an international collaborative study. Fam Cancer (2001) 1.13
Unbalanced germ-line expression of hMLH1 and hMSH2 alleles in hereditary nonpolyposis colorectal cancer. Cancer Res (1999) 1.06
Pathology of the hereditary colorectal carcinoma. Fam Cancer (2007) 1.04
Immunohistochemical detection of mismatch repair gene proteins as a useful tool for the identification of colorectal carcinoma with the mutator phenotype. J Pathol (2000) 1.04
New developments in Lynch syndrome (hereditary nonpolyposis colorectal cancer) and mismatch repair gene testing. Gastroenterology (2006) 1.04
Family history and molecular features of children, adolescents, and young adults with colorectal carcinoma. Gut (2005) 1.03
Involvement of hMSH6 in the development of hereditary and sporadic colorectal cancer revealed by immunostaining is based on germline mutations, but rarely on somatic inactivation. Int J Cancer (2002) 0.99
Evaluation of Bethesda guidelines in relation to microsatellite instability. Dis Colon Rectum (2001) 0.92
Increased sensitivity of colorectal cancer cell lines with microsatellite instability to 5-fluorouracil in vitro. Chin Med J (Engl) (2002) 0.77
Facilitating haplotype analysis by fully automated analysis of all chromosomes in human-mouse hybrid cell lines. Cytogenet Cell Genet (2001) 0.76
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg (2010) 4.59
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol (2011) 2.95
Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer (2010) 2.62
MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res (2009) 2.59
Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol (2008) 2.30
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer. BMC Cancer (2010) 2.10
Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist (2010) 1.91
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
Sentinel lymph node biopsy. BMJ (2004) 1.76
MiRNAs as biomarkers and therapeutic targets in cancer. Curr Opin Pharmacol (2010) 1.72
Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat (2011) 1.70
MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res (2008) 1.69
A review of expression profiling of circulating microRNAs in men with prostate cancer. BJU Int (2012) 1.60
The TGFBR1*6A/9A polymorphism is not associated with differential risk of breast cancer. Breast Cancer Res Treat (2009) 1.55
Dysregulated miR-183 inhibits migration in breast cancer cells. BMC Cancer (2010) 1.46
Oral cavity examination: beyond the core curriculum? Br J Oral Maxillofac Surg (2011) 1.45
MicroRNA-9 inhibition of cell proliferation and identification of novel miR-9 targets by transcriptome profiling in breast cancer cells. J Biol Chem (2012) 1.43
MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease. Int J Colorectal Dis (2011) 1.43
Aerosolized intraperitoneal local anesthetic for laparoscopic surgery: a randomized, double-blinded, placebo-controlled trial. World J Surg (2015) 1.42
Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. Am J Hum Genet (2013) 1.39
Evaluation and validation of candidate endogenous control genes for real-time quantitative PCR studies of breast cancer. BMC Mol Biol (2007) 1.29
Advances in mesenchymal stem cell-mediated gene therapy for cancer. Stem Cell Res Ther (2010) 1.29
11q13 is a susceptibility locus for hormone receptor positive breast cancer. Hum Mutat (2012) 1.26
The effect of breast cancer awareness month on internet search activity--a comparison with awareness campaigns for lung and prostate cancer. BMC Cancer (2011) 1.26
Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.23
Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristics. Breast Cancer Res Treat (2010) 1.20
Circulating miRNA signatures: promising prognostic tools for cancer. J Clin Oncol (2010) 1.20
Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. Int J Cancer (2009) 1.17
miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy. Int J Colorectal Dis (2012) 1.16
Complementary and alternative medicine use in oncology: a questionnaire survey of patients and health care professionals. BMC Cancer (2011) 1.16
Representation of cancer in the medical literature--a bibliometric analysis. PLoS One (2010) 1.15
Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS One (2012) 1.13
Breast cancer research output, 1945-2008: a bibliometric and density-equalizing analysis. Breast Cancer Res (2010) 1.12
Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Ann Surg (2009) 1.09
Identification of endogenous control genes for normalisation of real-time quantitative PCR data in colorectal cancer. BMC Mol Biol (2010) 1.06
Low penetrance breast cancer predisposition SNPs are site specific. Breast Cancer Res Treat (2008) 1.03
The therapeutic potential of microRNAs: disease modulators and drug targets. Pharm Res (2011) 1.01
Malignant phyllodes tumour with liposarcomatous differentiation, invasive tubular carcinoma, and ductal and lobular carcinoma in situ: case report and review of the literature. Patholog Res Int (2010) 1.00
A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. Hum Mol Genet (2013) 1.00
Circulating microRNAs: promising breast cancer Biomarkers. Breast Cancer Res (2011) 0.99
The effect of hysterectomy on colonoscopy completion: a systematic review and meta-analysis. Dis Colon Rectum (2014) 0.99
Mesenchymal Stem Cell-mediated delivery of the sodium iodide symporter supports radionuclide imaging and treatment of breast cancer. Stem Cells (2011) 0.97
Relationship between circulating and tissue microRNAs in a murine model of breast cancer. PLoS One (2012) 0.96
The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer. PLoS One (2012) 0.95
Digital rectal examination: national survey of undergraduate medical training in Ireland. Postgrad Med J (2007) 0.95
Mesenchymal stem cells in the colorectal tumor microenvironment: recent progress and implications. Int J Cancer (2012) 0.94
The sodium iodide symporter (NIS) and potential regulators in normal, benign and malignant human breast tissue. PLoS One (2011) 0.94
Smart phone apps: smart patients, steer clear. Patient Educ Couns (2012) 0.93
Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivo. Cancer Res (2008) 0.91
Role models and mentors in surgery. Am J Surg (2012) 0.91
Younger age as a prognostic indicator in breast cancer: a cohort study. BMC Cancer (2011) 0.91
Clinical applications of gene expression in colorectal cancer. J Gastrointest Oncol (2013) 0.91
Surgeon and breast unit volume-outcome relationships in breast cancer surgery and treatment. Ann Surg (2013) 0.90
Electronic follow-up of facial lacerations in the emergency department. J Telemed Telecare (2011) 0.89
Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev (2015) 0.88
miR-379 regulates cyclin B1 expression and is decreased in breast cancer. PLoS One (2013) 0.87
MicroRNA expression in colorectal cancer. Cancer Biomark (2012) 0.87
Estrogen withdrawal, increased breast cancer risk and the KRAS-variant. Cell Cycle (2015) 0.86